Q2 2020

Filed Aug 7, 2020 · 10-Q · 38 days after period end · 0001785982-20-000703

Q2 2020 · 10-Q

Revenue—

Net Income

-$928.60K

N/M vs Q2 2019

EPS Diluted

-$0.01

— vs Q2 2019

Operating Income-$111,909N/M

Operating Cash Flowderived-$55,715N/M

Same quarter

Metric	Q2 2020	Q2 2019	Q2 2017	Q2 2016
Revenue	—	—	$39.47K	$55.63K
Net Income	-$928.60K	-$130.29K	-$260.42K	-$163.00K
EPS Diluted	-$0.01	$0.00	-$0.01	-$0.01

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Bioxytran, Inc · CIK 1445815 · Engraved from SEC EDGAR